Quick Answer
enVVeno Medical Corp reported Operating Income Loss of -$20.90 million for the year ending 2025.
- enVVeno Medical Corp showed an increase of +12.3% in Operating Income Loss from 2024 to 2025.
- This data is from enVVeno Medical Corp's annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: -$1.23 million | Q3 2017: -$1.81 million | Q1 2018: -$1.46 million | Q2 2018: -$3.11 million | Q3 2018: -$1.49 million | Q1 2019: -$1.58 million | Q2 2019: -$1.96 million | Q3 2019: -$1.83 million | Q1 2020: -$1.51 million | Q2 2020: -$1.55 million | Q3 2020: -$1.92 million | Q1 2021: -$2.81 million | Q2 2021: -$2.39 million | Q3 2021: -$2.71 million | Q1 2022: -$5.34 million | Q2 2022: -$6.99 million | Q3 2022: -$6.15 million | Q1 2023: -$6.80 million | Q2 2023: -$6.81 million | Q3 2023: -$5.35 million | Q1 2024: -$5.50 million | Q2 2024: -$5.45 million | Q3 2024: -$6.17 million | Q1 2025: -$4.95 million | Q2 2025: -$7.05 million | Q3 2025: -$4.88 million.
- Over the full 9 years of available data (2017 to 2025), enVVeno Medical Corp's Operating Income Loss has declined by 242.4%.
- Historical annual values: Fiscal year 2025: -$20.90 million | Fiscal year 2024: -$23.83 million | Fiscal year 2023: -$25.24 million | Fiscal year 2022: -$24.93 million | Fiscal year 2021: -$16.89 million | Fiscal year 2020: -$9.14 million | Fiscal year 2019: -$7.68 million | Fiscal year 2018: -$7.85 million | Fiscal year 2017: -$6.10 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: